Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy
Cell Host & Microbe · 2026
DOI: 10.1016/j.chom.2026.02.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Host & Microbe, 2026. Verfasst von Baoyi Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China; CAS Key Laboratory for Biomedical Effect…. Hauptthemen laut MEDLINE: Immunotherapy, Probiotics, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Although pancreatic ductal adenocarcinoma (PDAC) tumors harbor unique intracellular bacteria, therapeutic strategies to harness them and overcome immunotherapy resistance remain elusive. Through 16S rDNA sequencing of PDAC tumors from 40 patients and screening of probiotic strains, we identified Bifidobacterium longum (B. longum) as capable of colonizing tumors and invading PDAC cells. In a murine orthotopic tumor model, B. longum's anti-tumor effects are exclusively driven by rapamycin-induced xenophagy. This xenophagy-mediated probiotic therapy, termed XenoPro, significantly suppresses tumor growth by presenting B. longum-derived neoantigens and eliciting robust CD4+ T cell activation and tumor-specific cytotoxicity. From 40 predicted neoantigens, a vaccine containing the top 12 immunogenic neoantigens showed potent anti-tumor effects and prolonged survival in murine models of PDAC, colorectal cancer, and melanoma. XenoPro, administered orally or intravenously, enhances immune cell infiltration and improves the efficacy of immune checkpoint inhibitors, offering a promising strategy for PDAC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China; CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscie…
- CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
- Department of Pathology, Peking University First Hospital, Beijing 100034, China.
- Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China.
- Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing 100034, China. Electronic address: yangyinmo@263.net.
- CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China; University of Chinese Ac…
Förderung
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
Zitieren
APA
Li, B., Liu, G., Zhu, Y., Chen, L., Zhang, N., Zhu, X., Sun, Y., Liu, X., Liu, W., Ma, Y., Tian, X., Yang, Y., & Zhu, M. (2026). Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2026.02.010
Vancouver
Li B, Liu G, Zhu Y, Chen L, Zhang N, Zhu X, et al. Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy. Cell Host & Microbe. 2026. doi:10.1016/j.chom.2026.02.010
BibTeX
@article{Li2026,
author = {Li, Baoyi and Liu, Guangnian and Zhu, Yu and Chen, Lin and Zhang, Nianhua and Zhu, Xiaojuan and Sun, Yixin and Liu, Xinxin and Liu, Weikang and Ma, Yongsu and Tian, Xiaodong and Yang, Yinmo and Zhu, Motao},
title = {Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy},
journal = {Cell Host & Microbe},
year = {2026},
doi = {10.1016/j.chom.2026.02.010}
}
EUVIMED